AptarGroup, Inc. (ATR) — ESG & Values Scores

Environment story

AptarGroup demonstrates moderate environmental performance with acknowledged climate risks and emerging sustainability initiatives, but critical gaps in emissions disclosure and net-zero target clarity significantly constrain the Environmental score. The company acknowledges physical climate risks (water scarcity, drought) and regulatory exposure (PFAS bans, carbon regulations), yet provides no disclosed Scope 1, 2, or 3 emissions baselines, renewable energy percentage, or binding net-zero target year. The 10-K emphasizes cost pressures from PCR resin sourcing for sustainable products and acknowledges customer demand for refillable/reusable solutions, but lacks quantified decarbonization infrastructure investments or third-party-verified emissions reduction pathways. No greenwashing red flags detected (no offset-reliance claims; no supply-chain obscuration), but the absence of material emissions data and a defined net-zero deadline triggers mandatory deductions under the rubric.

Criticisms on file

No disclosed Scope 1, 2, or 3 emissions baselines or net-zero target year
Source: ATR 10-K 2025 — Risk Factors section lacks any emissions metrics or climate commitment date
Indirect emissions from energy and transportation costs rising due to geopolitical disruption and supply-chain stress
Source: ATR 10-K 2025 — Item 1A Risk Factors: 'higher energy and other input costs' from Ukraine conflict; tariff-driven supply-chain volatility
Potential for increased operational emissions from elevated raw-material sourcing and transportation due to tariff-driven supply-chain fragmentation
Source: ATR 10-K 2025 — Item 1A Risk Factors: 2025 U.S. tariffs on China, Canada, Mexico; 'higher costs… and potential to disrupt global supply chain'

Disclosed initiatives

PCR Resin Integration for Sustainable Products

Company acknowledges investment in post-consumer recycled (PCR) resin for sustainable product offerings as a response to customer demand for refillable and reusable solutions.

Increases material costs; supports circular economy but lacks quantified emissions impact
PFAS Phase-Out Compliance

Company notes EU and U.S. state bans on PFAS materials in packaging; positioned to adapt manufacturing processes.

Regulatory compliance requirement; may drive process innovation but involves redesign costs
Climate Risk Monitoring

Company monitors physical climate risks (water scarcity, drought) and emerging carbon regulations; assesses cost of compliance responses.

Risk awareness documented; no quantified mitigation targets or timelines disclosed

Social story

AptarGroup's Social score reflects mixed performance: unionized workforce (primarily Europe and Latin America) with collective bargaining is an institutional strength, yet the company discloses no CEO-to-worker pay ratio, no leadership diversity metrics, and no supply-chain human-rights audit data. The 10-K references labor relations as 'satisfactory' and acknowledges union strike risk (particularly France) without evidence of recent disputes or NLRB complaints. No documented supply-chain audits for forced labor, conflict minerals, or living-wage verification appear in public filings. Turnover rates, diversity percentages, and pay-gap data are absent from the filing. The absence of documented union-suppression activity prevents deduction under the strictest rubric criteria, but lack of affirmative disclosure on diversity and pay equity limits the score.

Criticisms on file

No disclosed CEO-to-median-worker pay ratio
Source: ATR 10-K 2025 — Proxy/Executive Compensation section not provided in source documents; absence implies non-disclosure
No disclosed leadership diversity (executive/board) percentages or diversity initiatives
Source: ATR 10-K 2025 — No diversity metrics or programs mentioned in Risk Factors or governance sections
No disclosed supply-chain human-rights audits, forced-labor policies, or conflict-minerals verification
Source: ATR 10-K 2025 — Item 1A Risk Factors contains no supply-chain ethics, labor practices, or supply-source audit disclosures
Material strike/labor dispute risk in unionized European (France) facilities
Source: ATR 10-K 2025 — Item 1A Risk Factors: 'If disputes with our unions arise, or if our unionized workers… engage in a strike or other work stoppage, we could experience a significant disruption of operations'

Disclosed initiatives

Collective Bargaining Agreements

Majority of employees in Europe (especially France) and Latin America covered by union contracts negotiated at local or national level.

Institutional labor representation; wage and working condition standardization; potential operational disruption risk from strikes
Employee Retention Programs

Company acknowledges labor cost inflation and recruitment/retention challenges; identifies loss of key management as material risk.

Risk awareness documented; no quantified retention rates or competitive-compensation metrics disclosed

Governance story

AptarGroup's Governance score reflects sound structural controls (no dual-class share structure disclosed; board independence presumed adequate by absence of contrary disclosure) offset by material litigation exposure and ongoing antitrust/IP challenges. The company is defending patent infringement claims from Nemera (France, Germany, October 2025 EPO hearing allowed amended claim to continue) and faces an antitrust lawsuit filed by ARS Pharmaceuticals Operations (September 2025, U.S. District Court, Southern California) alleging anticompetitive conduct regarding component supply and seeking injunctive relief and damages. The company also initiated trade-secret litigation against ARS Pharmaceuticals (March 2025). No lobbying expenditure data or PAC contribution disclosures appear in the 10-K excerpt; no anti-climate regulation lobbying activities disclosed. Board independence percentage and detailed lobbying spend remain undisclosed. The multiplicity of active litigation (patent, antitrust, trade secret) represents material governance and legal risk.

Criticisms on file

Patent infringement litigation initiated by Nemera (May 2025, France and Germany; ophthalmic products)
Source: ATR 10-K 2025 — Item 1A Risk Factors and Note 13 Commitments and Contingencies: 'Nemera filed patent infringement actions against us in France and Germany relating to certain of our ophthalmic products. In October 2025, an EPO hearing invalidated Nemera's main patent claim while allowing an amended claim to continue.'
Antitrust lawsuit filed by ARS Pharmaceuticals Operations, Inc. (September 2025, U.S. District Court, Southern District of California)
Source: ATR 10-K 2025 — Item 1A Risk Factors and Note 13: 'In September 2025, ARS Pharmaceuticals Operations, Inc. filed an antitrust lawsuit against us in the United States District Court for the Southern District of California, alleging violations of U.S. competition laws related to supply of certain components and are seeking injunctive relief and damages.'
Trade-secret misappropriation litigation initiated by AptarGroup (March 2025, against ARS Pharmaceuticals, Inc. and ARS Pharmaceuticals Operations, Inc.)
Source: ATR 10-K 2025 — Item 1A Risk Factors and Note 13: 'In March 2025, we filed a lawsuit against ARS Pharmaceuticals, Inc. and ARS Pharmaceuticals Operations, Inc. alleging that our confidential information and trade secrets were improperly disclosed and used.'
No disclosed board independence percentage or detailed governance composition metrics
Source: ATR 10-K 2025 — Risk Factors section does not disclose board independence %; Proxy statement not provided in source documents
No disclosed lobbying expenditures or PAC contributions
Source: ATR 10-K 2025 — No lobbying spend or political contribution data disclosed in Risk Factors or provided sections

Disclosed initiatives

Legal Compliance and Anti-Corruption Programs

Company acknowledges compliance with anti-corruption, trade, sanctions, and competition laws; implements policies and training to ensure employee and intermediary adherence.

Governance framework documented; effectiveness and third-party audit status not disclosed
Data Privacy and GDPR/CPRA Compliance

Company acknowledges compliance obligations under EU GDPR and California CPRA; identifies complexity and cost of privacy law adherence.

Regulatory compliance measure; no specific governance enhancements or audit results disclosed
Cybersecurity Risk Management

Company conducts periodic system vulnerability testing via third parties; employs employee training, network monitoring, authentication mechanisms, and data protection standards.

Risk mitigation framework; no material cybersecurity breaches reported to date

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of AptarGroup, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open AptarGroup, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)